NCATS experts are using a technology called matrix combination screening, which quickly narrows down a long list of potential drug combinations to find those with the most potential to help patients. The matrix screening approach uses NCATS’ high-throughput robotic screening platform to quickly conduct millions of tests to assess the effects of a combination of therapeutic compounds on cellular, molecular or biochemical processes that are relevant to a disease of interest.
Explore selected matrix screening projects below:
- Development of Novel Chemical Genomic Platforms for Pathogenic Protozoa
- High-Throughput Combinatorial Screening Identifies Drugs that Cooperate with Ibrutinib to Kill Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Cells
- High-Throughput Drug Screening Identifies Novel Therapeutic Options for BPDCN
- Identification of a Synergistic Combination Between PARP Inhibitors and NAMPT Inhibitors in Ewing Sarcoma
- mQC: A Quality Control Metric for High-Throughput Combination Screening
- PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
